Intelligent Bio 2026 Q1 Earnings EPS Loss Narrows 50% Despite $2.99M Net Loss

Intelligent Bio (INBS) reported fiscal 2026 Q1 earnings on Nov 12, 2025, with revenue rising 27.5% year-over-year to $1.11 million. The company narrowed its per-share loss by 50% to $0.35 but posted a wider $2.99M net loss. Management guided toward sustained revenue growth through consumable sales, international expansion, and FDA clearance, though risks around regulatory timing remain.

Revenue

The total revenue of Intelligent Bio increased by 27.5% to $1.11 million in 2026 Q1, up from $872,287 in 2025 Q1. Cartridge sales accounted for $640,300, or 57.59% of total revenue, up from 51.1% in the prior year quarter. This shift reflects the company’s strategic focus on recurring consumable sales, which now represent nearly 58% of revenue.

Earnings/Net Income

Intelligent Bio narrowed losses to $0.35 per share in 2026 Q1 from a loss of $0.70 per share in 2025 Q1 (50.0% improvement). Meanwhile, the company’s net loss widened to $-2.99 million in 2026 Q1, representing an 11.1% increase from the $-2.69 million loss recorded in 2025 Q1. Despite the net loss widening, the EPS loss improved significantly, indicating progress in cost management.

Price Action

The stock price of Intelligent Bio has edged down 0.96% during the latest trading day, has dropped 3.62% during the most recent full trading week, and has plummeted 25.89% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Intelligent Bio (INBS) shares on the date of its revenue raise announcement and holding for 30 days yielded moderate returns, but underperformed the market. The 30-day holding period provided some capital appreciation, but the overall performance was muted due to the volatility in INBS’s stock price. This approach captured some of the post-revenue raise momentum but also exposed investors to potential short-term fluctuations. The strategy’s beta of 1.2 indicates it was moderately risky, aligning with the high beta of INBS’s stock, which suggests greater volatility compared to the market. The strategy capitalized on INBS’s revenue raise announcements, which coincided with periods of positive market sentiment towards the company. The 30-day holding period exposed investors to INBS’s typical volatility, leading to some drawdowns, particularly in periods of broader market corrections. Over the 3-year backtest, the strategy’s returns were slightly below the NASDAQ Composite, indicating that while there was some growth, it was not robust enough to outpace the broader market index. This strategy could be improved by incorporating more sophisticated risk management techniques, such as stop-loss orders or position sizing adjustments based on market conditions and INBS’s volatility. Additionally, considering a longer holding period or employing a more robust entry and exit framework might enhance returns and reduce the impact of INBS’s known volatility.

CEO Commentary

Harry Simeonidis, President and CEO at Intelligent Bio Solutions, highlighted record quarterly revenue of $1.11 million, reflecting 32% sequential and 28% year-over-year growth driven by cartridge sales and customer base expansion. He emphasized the company’s strategic focus on consumable cartridge sales, which accounted for 57.59% of revenue, as a key growth driver, alongside improved operational efficiency and gross margin expansion (46.6% year-over-year). Simeonidis expressed optimism about sustained growth as the company advances toward FDA clearance and U.S. market entry, noting that the results validate their business model and international market adoption.

Guidance

The company indicated forward-looking expectations of sustained revenue growth through consumable-focused operations, international expansion, and regulatory milestones, including FDA clearance. Management stated it is "well positioned to capitalize on the growth opportunities ahead," citing strong returns on strategic investments and improved customer acquisition metrics. Forward-looking statements also referenced the potential for commercial benefits from partnerships, such as the global distribution agreement for SmarTest® Patch technology, and the ability to secure large-scale deployments, though risks related to regulatory approvals and market adoption were acknowledged.

Additional News

Intelligent Bio Solutions announced the launch of the SmarTest® Patch, a wearable device for continuous drug detection, and secured a global distribution agreement with SMARTOX for markets outside the U.S. and Canada. The company also signed a multi-site contract in London covering 4,400 staff, signaling commercial validation. Additionally, it added 33 new customer accounts, bringing total active accounts to 492 across 24+ countries. Management aims to expand into new customer segments, including major sporting organizations, law enforcement, and commercial airlines, while advancing its FDA 510(k) submission for opiate codeine detection.